In the context of bilateral nephrectomy, rosuvastatin acts on these hypoxia-inducible factors across various organs and tissues, offering a strategic approach to anemia management by promoting erythropoietin synthesis outside the kidneys [50,51,54]. This evidence concerns the gene EPO and anemia (phenotype).